Stem cell derived islet differentiation
AssigneeVertex Pharmaceuticals Incorporated
InventorsFelicia J. Pagliuca, George Harb, Lillian Ye
Life of this patent
Estimating the term…
Abstract
Provided herein are methods of producing β cells and precursors thereof utilizing a Wnt signaling inhibitor or PKC activator, or both. Also provided herein are in vitro cultures comprising said cells, methods of treating a subject with a disease characterized by high blood sugar levels over a prolonged period of time by administering said cells, and devices for encapsulating said cells.
Claims20
A composition comprising PDX1-positive, NKX6.1-positive pancreatic progenitor cells, a WNT signaling inhibitor, and one or more of a thyroid receptor signaling pathway activator, a protein kinase C activator, or a transforming growth factor (TGF)-β signaling pathway inhibitor, wherein the WNT signaling inhibitor is present at a concentration of 0.1 μM to 10 μM.
Dependencies are inferred from the claim text.